Date: 10.08.2022

Certification of Collaboration for Research

This is to acknowledge that Prof. (Dr.) Satyanarayan Pattnaik, Department of Pharmaceutics of Talla Padmavathi College of Pharmacy, Warangal, Telangana, India has been in active collaboration support since 2021 with Prof. (Dr.) Santanu Chakraborty, Divisional In-charge of Pharmaceutics Division, Dr. B. C. Roy College of Pharmacy & Allied Health Sciences, Durgapur, WB, India. In this collaboration, we contributed to mentoring the design of various research proposals, experiments, instruments and many more.

We have shared our ideas and views in writing of various review articles, book chapters and research articles. We have actively participated in achieving Indian Design Patents as well as UK Design Patent. Apart from this, we also jointly work on various formulation design and development. We also published various research as well as review papers in various international reputed journals.

We are hopeful to carry this collaborative research in near future also.

Name: Prof. (Dr.) Santanu Chakraborty
Designation: Professor and Divisional In-Charge of Pharmaceutics
Dr. B. C. Roy College of Pharmacy & Allied Health Sciences
Durgapur, WB, India

Signature with Seal (1st Party)
Date: 10-08-2022

Name: Prof. (Dr.) Satyanarayan Pattnaik
Designation: Professor, Department of Pharmaceutics
Talla Padmavathi College of Pharmacy,
Warangal, Telangana, India.

Signature with Seal (2nd Party):
Date: 10-08-2022

Prof. (Dr.) Samir Kumar Samanta
M. Pharm., Ph.D (J.U.)
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206

Send Orders for Reprints to reprints@benthamscience.net

Recent Advances in Drug Delivery & Formulation, 2023, *17*, 132-151

REVIEW ARTICLE

BENTHAM SCIENCE

A Critical Appraisal of Lipid Nanoparticles Deployed in Cancer Pharmacotherapy

Santanu Chakraborty[1], Manami Dhibar[1], Aliviya Das[2], Kalpana Swain[3] and Satyanarayan Pattnaik[3,*]

[1]*Formulation Development Research Unit, Department of Pharmaceutics, Dr. B. C. Roy College of Pharmacy and AHS, Durgapur-713206, West Bengal, India;* [2]*Calcutta Institute of Pharmaceutical Technology & AHS, Uluberia, Howrah, West Bengal, India;* [3]*Division of Advanced Drug Delivery, Talla Padmavathi College of Pharmacy, Warangal, India*

ARTICLE HISTORY

Received: November 07, 2022
Revised: June 16, 2023
Accepted: June 21, 2023

DOI
10.2174/2667387817666230726140745

CrossMark

Abstract: Treatment modalities of various cancers and the delivery strategies of anticancer agents have evolved significantly in the recent past. The severity and fatality of the disease and hurdles to the effective delivery of therapeutic agents have drawn the attention of researchers across the world for proposing novel and effective drug delivery strategies for anticancer therapeutics. Attempts have been made to propose solutions to the diverse limitations like poor pharmacokinetics and higher systemic toxicities of the traditional delivery of anticancer agents. Nanotechnology-based drug delivery systems including lipid-based nanocarriers have demonstrated significant efficiency in this scenario. The review critically assessed the different types of lipid nanocarrier systems for the effective and optimal delivery of anticancer therapeutic agents. The diverse synthesis approaches are discussed for the laboratory scale and commercial development of different categories of lipid nanocarriers. Further, their application in anticancer drug delivery is illustrated in detail followed by a critical appraisal of their safety and toxicity.

Keywords: Lipid-based nanocarriers, nanomedicine, cancers, nanotoxicity, liposomes, solid lipid nanoparticles.

1. INTRODUCTION

Cancer is the world's second-biggest cause of death and treating it remains a serious problem as the number of cases rises. Patients with cancer are treated with a variety of methods, including surgery, chemotherapy, radiotherapy, and immunotherapy. Chemotherapy, on the other hand, may be the only way to improve survival odds once cancer has spread and become metastatic [1]. Except for breast cancer, which is treated with hormone treatment or immunotherapy, cytotoxic drugs are still the most common type of cancer chemotherapy. Anticancer drugs are usually cytotoxic agents which treat cancer by acting against the cancerous cells. These drugs preferentially target cancer cells because they frequently undergo fast growth and proliferation [2]. Despite decades of research, there are still significant unmet medical requirements in cancer detection and treatment. However, there are a large number of potentially effective therapeutic agents (both biopharmaceutical and small-molecule drug-related) that are either too large highly charged, unstable, and not too soluble to reach cancer target cells without the use of delivery "vehicles." [3]. The last few decades have witnessed a significant contribution of molecular biology in understanding cancer biology in a better manner. This has paved the way for the development of therapeutic compounds that target the source of the problem: the molecular and cellular processes that lead to disease development. Unfortunately, many drug molecules are therapeutically ineffective due to diverse reasons including their poor aqueous solubility, and hence, require specialized delivery vehicles. In some cases, medications are unable to pass through cell membranes, resulting in insufficient concentrations at the target region. To overcome this, substantial pharmacological doses are required, resulting in side effects [4, 5]. To overcome this, Cancer nanotechnology has emerged as a cancer treatment method for anticancer medication delivery [6]. Nanomedicine has evolved as a viable technique not only for enhancing drug therapeutic index but also for overcoming biological obstacles over the last 20 years. Nanoparticles as drug delivery systems are made up of inorganic or organic components with diameters ranging from 1 to 1000 nanometres [7]. They can prevent chemotherapeutic drugs from degrading too quickly, extending their biological half-life. The first nanomedicines to be commercialized in cancer therapy were liposomes for parenteral delivery [8-11]. Polymeric micelles, or nanoscale supramolecular constructions made out of amphiphilic block copolymers, are proving to be effective drug delivery vehicles for lipophilic drugs [12]. Liposomes, which consist of one or more lipid bilayers encapsulating an aqueous core, are now the most popular nanoparticle drug delivery vehi-

*Address correspondence to this author at the Division of Advanced Drug Delivery, Talla Padmavathi College of Pharmacy, Warangal, India; Tel: +91-7386752616; E-mail: drsatyapharma@gmail.com

2667-3886/23 $65.00+.00

Recent Advances in Drug Delivery & Formulation

ESSENTIAL OILS

Extraction Methods and Applications

Edited By
Inamuddin
Tariq Altalhi
Jorddy Neves Cruz



Scrivener Publishing
WILEY

Essential Oils

Scrivener Publishing
100 Cummings Center, Suite 541J
Beverly, MA 01915-6106

Publishers at Scrivener
Martin Scrivener (martin@scrivenerpublishing.com)
Phillip Carmical (pcarmical@scrivenerpublishing.com)

Prof. (Dr.) Samir Kumar Samanta
M. Pharm., Ph.D (J.U.)
Principal
Dr. B. C. Roy College of Pharmacy & AHS
Durgapur, West Bengal-713206

Essential Oils

Extraction Methods and Applications

Edited by

Inamuddin

Scrivener
Publishing

WILEY

This edition first published 2023 by John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA and Scrivener Publishing LLC, 100 Cummings Center, Suite 541J, Beverly, MA 01915, USA

For more information about Scrivener publications please visit www.scrivenerpublishing.com.

Wiley Global Headquarters
111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Limit of Liability/Disclaimer of Warranty
While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchant-ability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read.

Library of Congress Cataloging-in-Publication Data

ISBN 9781119829355

Front cover image: Pixabay.com
Cover design by Russell Richardson

Set in size of 11pt and Minion Pro by Manila Typesetting Company, Makati, Philippines

Printed in the USA

10 9 8 7 6 5 4 3 2 1

Contents